Thus, SGLT2 inhibitors might become a relevant therapeutic approach for hyperinsulinemia related conditions, other than T2DM, namely obesity and prediabetes. This evidence concerns the gene SLC5A2 and obesity due to melanocortin 4 receptor deficiency.